Current methods of diagnosis and monitoring of a systemic amyloidosis course

Terapevticheskii Arkhiv

Volumn 83, Issue 8, 2011, Pages 48-54

  Rameev, V V ^a   Kozlovskaya, L V ^a   Malinina, E A ^a   Serova, A G ^a   Kogarko, I N ^b   Kogarko, B S ^b   Lyubimova, N V ^c  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b SEMENOV INSTITUTE OF CHEMICAL PHYSICS   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

AA amyloidosis; AL amyloidosis; Free light chains of immunoglobulins; Freelite; SAA

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; SERUM AMYLOID A;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PROGNOSIS; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PROGNOSIS; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 80053510019     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Glenner G. G., Terry W., Harada M. et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analysis. Science 1971; 171: 1150-1151.
2. Benditt E. P., Eriksen N. Chemical classes of amyloid substance. Am. J. Pathol. 1971; 65: 231-252.
3. Levin M., Pras M., Franklin E. C. Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component. J. Exp. Med. 1973; 138: 373-380.
4. Liepnieks J. J., Kluve-Beckerman B., Benson M. D. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum-amyloid Al. Biochim. Biophys. Acta 1995; 1270: 81-86.
5. Bradwell A. R. Serum free light chain analysis. 4th ed.: The Binding Site Ltd.; 2006.
6. Sipe J. D. ed. Amyloid proteins. The beta sheet conformation and disease. WILEY-VCH; 2005.
7. Moriguchi M., Terai C, Koseki Y. et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA- amyloidosis in patients with rheumatoid arthritis. Hum. Genet. 1999; 105: 360-366. (Pubitemid 29476289)
8. Moriguchi M., Terai C, Kaneko H. et al. A novel single-nucle-otide polymorphism at the 5-lanking region of SAA1 associated with risk or type AA amyloidosis secondary to rheumatoid arthritis. Arthr. and Rheum. 2001; 44: 1266-1272. (Pubitemid 32537524)
9. Yamada T., Okuda Y., Takasugi K. et al. An allele of serum amyloid Al associated with amyloidosis in both Japanese and Caucasians. Amyloid: J. Protein Folding Disord. 2003; 10: 7-11. (Pubitemid 36520923)
10. Booth D. R., Booth S. E., Gillimore J. D. et al. SAA1 alleles as risk factors in reactive systemic amyloidosis. Amyloid: Int. J. Exp. Clin. Invest. 1998; 5: 262-265. (Pubitemid 128690765)
11. Cazeneuve C, Ajrapetyan H., Papin S. et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am. J. Hum. Genet. 2000; 67: 1136-1143.
12. Medlej-Hashim M., Delague V., Chouery E. et al. Amyloidosis in familial Mediterranean fever patients: correlation with ME-FV genotype and SAA1 and MICA polymorphisms effects. BMC Med. Genet. 2004; 5: 4.
13. Gershoni-Baruch R., Brik R., Zacks N. et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthr. and Rheum. 2003; 48: 1149-1155. (Pubitemid 36418258)
14. Bakkaloglu A., Duzova A., Ozen S. et al. Influence of serum amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. J. Rheumatol. 2004; 31: 1139-1142. (Pubitemid 38715890)
15. Akar N., Hasipek M., Akar E. et al. Serum amyloid Al and tumor necrosis factor-alpha alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. Amyloid: J. Protein Folding Disord 2003; 10: 12-16. (Pubitemid 36520924)
16. Gillmore J. D., Lovat L. B., Persey M. R. et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-29. (Pubitemid 32709735)
17. Baba A., Takahashi T, Kasama T. et al. A novel polymorphism of human serum amyloid A protein, SAA1 is characterized by alanines at both residues 52 and 57. Biochim. Biophys. Acta 1992; 1180 (2): 615-620.
18. Baba S., Masago S. A., Takahashi T. et al. A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum. Mol. Genet. 1995; 4: 1083-1087.
19. Magy N,. Benson M. D., Liepnieks J. J., Kluve-Beckerman B. Cellular events associated with the initial phase of AA amy-loidogenesis: insights from a human monocyte model. Amyloid 2007; 14 (1): 51-63. (Pubitemid 46491169)
20. Kyle R. A., Gertz M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995; 32 (1): 45-59. (Pubitemid 24370135)